Sandoz Group AG (OTCMKTS:SDZNY - Get Free Report) shares hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $52.21 and last traded at $51.95, with a volume of 182726 shares changing hands. The stock had previously closed at $51.12.
Wall Street Analysts Forecast Growth
Separately, Royal Bank of Canada upgraded shares of Sandoz Group from a "hold" rating to a "moderate buy" rating in a research report on Friday, May 2nd.
Read Our Latest Stock Analysis on Sandoz Group
Sandoz Group Stock Up 0.1%
The business has a 50 day simple moving average of $44.00 and a 200-day simple moving average of $44.11.
About Sandoz Group
(
Get Free Report)
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.
Featured Articles
Before you consider Sandoz Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sandoz Group wasn't on the list.
While Sandoz Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
